Follow
Matts Kågedal
Matts Kågedal
Bioarctic
Verified email at bioarctic.com
Title
Cited by
Cited by
Year
Use of the intestinal bile acid transporter for the uptake of cholic acid conjugates with HIV-1 protease inhibitory activity
M Kågedahl, PW Swaan, CT Redemann, M Tang, CS Craik, FC Szoka, ...
Pharmaceutical research 14, 176-180, 1997
651997
A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066—estimating occupancy in the absence of a reference region
M Kågedal, Z Cselényi, S Nyberg, P Raboisson, L Ståhle, P Stenkrona, ...
Neuroimage 82, 160-169, 2013
532013
Modelling a spontaneously reported side effect by use of a Markov mixed-effects model
PH Zingmark, M Kågedal, MO Karlsson
Journal of pharmacokinetics and pharmacodynamics 32, 261-281, 2005
492005
Model‐Informed Therapeutic Dose Optimization Strategies for Antibody–Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration–Approved Antibody–Drug …
MZ Liao, D Lu, M Kågedal, D Miles, D Samineni, SN Liu, C Li
Clinical Pharmacology & Therapeutics 110 (5), 1216-1230, 2021
452021
Blood–brain barrier penetration of zolmitriptan—modelling of positron emission tomography data
M Bergström, R Yates, A Wall, M Kågedal, S Syvänen, B Långström
Journal of pharmacokinetics and pharmacodynamics 33, 75-91, 2006
422006
Development of a subcutaneous fixed‐dose combination of pertuzumab and trastuzumab: results from the phase Ib dose‐finding study
WP Kirschbrown, C Wynne, M Kågedal, R Wada, H Li, B Wang, I Nijem, ...
The Journal of Clinical Pharmacology 59 (5), 702-716, 2019
402019
Time‐to‐event analysis of polatuzumab vedotin‐induced peripheral neuropathy to assist in the comparison of clinical dosing regimens
D Lu, WR Gillespie, S Girish, P Agarwal, C Li, J Hirata, YW Chu, ...
CPT: Pharmacometrics & Systems Pharmacology 6 (6), 401-408, 2017
402017
Norepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR
S Nyberg, A Jucaite, A Takano, M Kågedal, Z Cselényi, C Halldin, L Farde
International Journal of Neuropsychopharmacology 16 (10), 2235-2244, 2013
372013
Distribution of zolmitriptan into the CNS in healthy volunteers: a positron emission tomography study
A Wall, M Kågedal, M Bergström, E Jacobsson, D Nilsson, G Antoni, ...
Drugs in R & D 6, 139-147, 2005
312005
Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers
M Kågedal, Z Cselényi, S Nyberg, S Jönsson, P Raboisson, P Stenkrona, ...
Neuroimage 61 (4), 849-856, 2012
302012
Dose-dependent binding of AZD3783 to brain 5-HT1B receptors in non-human primates and human subjects: a positron emission tomography study with [11C …
K Varnäs, S Nyberg, P Karlsson, ME Pierson, M Kågedal, Z Cselényi, ...
Psychopharmacology 213, 533-545, 2011
302011
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
S Kawakatsu, R Bruno, M Kågedal, C Li, S Girish, A Joshi, B Wu
British Journal of Clinical Pharmacology 87 (6), 2493-2501, 2021
282021
True nasopharyngeal absorption of zolmitriptan after administration via nasal spray in healthy male volunteers
M Kågedal, PH Zingmark, C Hedlund, R Yates
American Journal of Drug Delivery 3, 133-140, 2005
22*2005
PET-measured occupancy of the norepinephrene transporter by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects
S Nyberg, A Takano, A Jucaite, P Karlsson, D McCarthy, M Kagedal, ...
European Neuropsychopharmacology 18, S270-S270, 2008
202008
Intrinsic and extrinsic pharmacokinetic variability of small molecule targeted cancer therapy
E Reyner, B Lum, J Jing, M Kagedal, JA Ware, LJ Dickmann
Clinical and Translational Science 13 (2), 410-418, 2020
182020
Evaluation of the effects of a metabotropic glutamate receptor 5‐antagonist on electrically induced pain and central sensitization in healthy human volunteers
J Kalliomäki, K Huizar, M Kågedal, B Hägglöf, M Schmelz
European Journal of Pain 17 (10), 1465-1471, 2013
162013
A study of organic acid transporter-mediated pharmacokinetic interaction between NXY-059 and cefuroxime.
M Kagedal, D Nilsson, G Huledal, I Reinholdsson, YF Cheng, N Asenblad, ...
Journal of clinical pharmacology 47 (8), 1043-1049, 2007
162007
A new method to model and predict progression free survival based on tumor growth dynamics
J Yu, N Wang, M Kågedal
CPT: pharmacometrics & systems pharmacology 9 (3), 177-184, 2020
152020
Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)
SC Chen, M Kagedal, Y Gao, B Wang, ML Harle-Yge, S Girish, J Jin, C Li
Cancer Chemotherapy and Pharmacology 80, 1147-1159, 2017
152017
Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models
R Bruno, P Chanu, M Kågedal, F Mercier, K Yoshida, J Guedj, C Li, ...
British journal of cancer 129 (9), 1383-1388, 2023
132023
The system can't perform the operation now. Try again later.
Articles 1–20